Award
National Cancer Institute PAR-21-329
Mechanistic Insight to Predict and Prevent Nilotinib-Induced Artery Disease
Recipient
Northwestern University
Awarded
July 27, 2026
Identifier
PAR-21-329
NIH grant awarded by the National Cancer Institute to study genetic markers related to Nilotinib-induced artery disease in chronic myelogenous leukemia patients, aiming to predict and prevent adverse effects.
Description
This NIH grant aims to study genetic markers associated with adverse effects of Nilotinib in treating chronic myelogenous leukemia, with a focus on preventing artery disease through genomic and pharmacological approaches.